首页> 外文期刊>Brain research >Pretreatment with rosuvastatin protects against focal cerebral ischemia/reperfusion injury in rats through attenuation of oxidative stress and inflammation
【24h】

Pretreatment with rosuvastatin protects against focal cerebral ischemia/reperfusion injury in rats through attenuation of oxidative stress and inflammation

机译:罗苏伐他汀预处理可减轻氧化应激和炎症反应,从而防止大鼠局灶性脑缺血/再灌注损伤

获取原文
获取原文并翻译 | 示例
           

摘要

This study aimed to examine the potential protective effect of rosuvastatin against cerebral ischemia/reperfusion injury and its mechanisms. Forty-eight male SD rats underwent 90 min of transient middle cerebral artery occlusion (tMCAO), followed by reperfusion. Rats were orally given (1) rosuvastatin 1 mg/kg, (2) rosuvastatin 10 mg/kg or (3) water (vehicle) once a day from 7 days before to 1 day after induction of tMCAO. Neurological score, infarct volume, and oxidative stress-related molecules (assessed by immunohistochemistry, dihydroethidium staining, or western blotting) were estimated at 24 h after reperfusion. Rosuvastatin prevented the impairment of neurological function and decreased the infarct volume, compared with the vehicle group. The increases in activated microglia, macrophage, and superoxide levels usually caused by ischemia/reperfusion were significantly ameliorated by rosuvastatin. Rosuvastatin also inhibited the upregulation of gp91phox and p22phox, phosphorylation of nuclear factor-kappa B, and induction of cyclooxygenase 2 and inducible nitric oxide synthase, compared with vehicle. The results suggest that pretreatment with rosuvastatin may be a promising therapeutic strategy for cerebral ischemia/reperfusion injury, through attenuation of oxidative stress and inflammation.
机译:本研究旨在探讨瑞舒伐他汀对脑缺血/再灌注损伤的潜在保护作用及其机制。 48只雄性SD大鼠经历了90分钟的短暂性大脑中动脉闭塞(tMCAO),然后进行了再灌注。在诱导tMCAO之前的7天到1天之间,每天一次给大鼠口服(1)罗舒伐他汀1 mg / kg,(2)罗舒伐他汀10 mg / kg或(3)水(载体)。在再灌注后24小时,估计神经学评分,梗塞体积和与氧化应激相关的分子(通过免疫组织化学,二氢乙啶染色或蛋白质印迹评估)。与赋形剂组相比,瑞舒伐他汀可预防神经功能损害并减少梗塞体积。瑞舒伐他汀可明显改善通常由缺血/再灌注引起的活化小胶质细胞,巨噬细胞和超氧化物水平的增加。与赋形剂相比,瑞舒伐他汀还抑制gp91phox和p22phox的上调,抑制核因子-κB的磷酸化以及诱导环加氧酶2和可诱导的一氧化氮合酶。结果表明,瑞舒伐他汀预处理可能通过减轻氧化应激和炎症反应而成为治疗脑缺血/再灌注损伤的一种有前途的治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号